EXEL (Exelixis) Cyclically Adjusted FCF per Share: $1.56 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EXEL Exelixis Inc EXEL
88 GF Score
Price $53.69
GF Value $45.73
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Exelixis Cyclically Adjusted FCF per Share?

Exelixis EXEL -1.31% 88 Cyclically Adjusted FCF per Share is $1.56 as of Jun. 2026. GuruFocus rates EXEL with a GF Score™ of 88/100 and a GF Value™ of $45.73 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Exelixis's adjusted free cash flow per share for the three months ended in Jun. 2026 was $1.149. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $1.56 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Exelixis's average Cyclically Adjusted FCF Growth Rate was 39.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 55.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Exelixis was 75.30% per year. The lowest was -8.50% per year. And the median was 13.50% per year.

As of today (2026-08-20), Exelixis's current stock price is $53.69. Exelixis's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $1.56. Exelixis's Cyclically Adjusted Price-to-FCF of today is 34.42.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Exelixis was 296.00. The lowest was 29.67. And the median was 40.06.


Exelixis  (NAS:EXEL) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Exelixis's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=53.69/1.56
=34.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Exelixis was 296.00. The lowest was 29.67. And the median was 40.06.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Exelixis Cyclically Adjusted FCF per Share Related Terms


Exelixis Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Exelixis's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis Cyclically Adjusted FCF per Share Chart

Exelixis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.37 0.58 0.97 1.39

Exelixis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.12 1.25 1.39 1.42 1.56

EXEL vs MDGL, AXSM, ARWR: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Exelixis's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Exelixis's Cyclically Adjusted Price-to-FCF falls into.


EXEL
88GF Score
Exelixis Inc EXEL
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exelixis Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Exelixis's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.149/333.9520*333.9520
=1.149

Current CPI (Jun. 2026) = 333.9520.

Exelixis Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.023 241.428 -0.032
201612 0.293 241.432 0.405
201703 0.220 243.801 0.301
201706 0.013 244.955 0.018
201709 0.117 246.819 0.158
201712 0.114 246.524 0.154
201803 0.220 249.554 0.294
201806 0.199 251.989 0.264
201809 0.479 252.439 0.634
201812 0.326 251.233 0.433
201903 0.506 254.202 0.665
201906 0.414 256.143 0.540
201909 0.233 256.759 0.303
201912 0.479 256.974 0.622
202003 0.168 258.115 0.217
202006 0.298 257.797 0.386
202009 0.038 260.280 0.049
202012 0.059 260.474 0.076
202103 0.081 264.877 0.102
202106 0.499 271.696 0.613
202109 0.214 274.310 0.261
202112 0.249 278.802 0.298
202203 0.440 287.504 0.511
202206 0.058 296.311 0.065
202209 0.314 296.808 0.353
202212 -0.119 296.797 -0.134
202303 0.110 301.836 0.122
202306 0.347 305.109 0.380
202309 0.074 307.789 0.080
202312 -0.008 306.746 -0.009
202403 0.166 312.332 0.177
202406 0.322 314.175 0.342
202409 0.899 315.301 0.952
202412 0.771 315.605 0.816
202503 0.656 319.799 0.685
202506 0.160 322.561 0.166
202509 1.018 324.800 1.047
202512 1.181 324.054 1.217
202603 0.934 330.213 0.945
202606 1.149 333.952 1.149

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $1.56 mean?
Exelixis (EXEL) has a Cyclically Adjusted FCF per Share of $1.56 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Exelixis and its competitors.
Is Exelixis' Cyclically Adjusted FCF per Share too high?
Exelixis' current Cyclically Adjusted FCF per Share is $1.56. Overall, Exelixis has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' Cyclically Adjusted FCF per Share compare to MDGL and AXSM?
Exelixis' Cyclically Adjusted FCF per Share of $1.56 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Exelixis and its competitors. Exelixis's current Cyclically Adjusted FCF per Share is $1.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (EXEL) is currently considered Modestly Overvalued. The stock's GF Value™ is $45.73, compared to a current price of $53.69 — trading 17.4% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $1.56. Exelixis' overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Exelixis (EXEL), the current Cyclically Adjusted FCF per Share is $1.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exelixis (EXEL) Overvalued in 2026?

Based on GuruFocus' analysis, Exelixis stock appears to be overvalued. The current stock price of $53.69 is trading 17.4% above its estimated GF Value™ of $45.73. GuruFocus considers Exelixis to be Modestly Overvalued.

Key valuation signals for EXEL:

  • Cyclically Adjusted FCF per Share: $1.56
  • GF Value™: $45.73 vs. price of $53.69 (17.4% above fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the EXEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Exelixis Business Description

Address 1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
88GF Score

Get the complete analysis for EXEL

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.69
Price
$45.73
GF Value